Clinical studies suggest the therapeutic potential of psychedelics, including ayahuasca,
DMT, psilocybin, and LSD, in stress-related disorders. These substances induce cognitive …

Mounting evidence suggests safety and efficacy of psychedelic compounds as potential
novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug …

Disorders of the nervous system are challenging to study and treat due to the relative
inaccessibility of functional human brain tissue for research. Stem cell-derived 3D human …

In addition to producing profound subjective effects following acute administration,
psychedelic compounds can induce beneficial behavioral changes relevant to the treatment …

methoxy‐N, N‐dimethyltryptamine (5‐MeO‐DMT) is a naturally occurring tryptamine that
primarily acts as an agonist at the 5‐HT1A and 5‐HT2A receptors, whereby affinity for the 5 …

Background 5-methoxy-N, N-dimethyltryptamine (hereinafter referred to as 5-MeO-DMT) is a
psychedelic substance found in the secretion from the parotoid glands of the Bufo alvarius …

Despite preclinical evidence for psychedelic-induced neuroplasticity, confirmation in
humans is grossly lacking. Given the increased interest in using low doses of psychedelics …

Serotonergic psychedelics are emerging as potential antidepressant therapeutic tools, as
suggested in a recent randomized controlled trial with ayahuasca for treatment-resistant …

Depression and anxiety disorders are debilitating diseases resulting in substantial economic
costs to society. Traditional antidepressants often take weeks to months to positively affect …

The prevalence of dementia and other neurodegenerative diseases is rapidly increasing in
aging nations. These relentless and progressive diseases remain largely without disease …